REG - OptiBiotix Health - Exercise of warrants

OptiBiotix HealthAnnouncement

09/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220309:nRSI1089Ea&default-theme=true

RNS Number : 1089E  OptiBiotix Health PLC  09 March 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Exercise of warrants

 

OptiBiotix Health plc (AIM:
OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol, blood pressure, diabetes, announces that it has received
notification to exercise warrants over 60 new ordinary shares of 2p each in
the capital of the Company ("Ordinary Shares"). The exercise price of the
warrants was 8p per share, providing the Company with proceeds of £4.80.

 

Application will be made for the 60 new Ordinary Shares to be admitted to
trading on AIM, which is expected to occur at 8.00 a.m. on or around 14 March
2022. The new Ordinary Shares will rank pari passu with the existing
Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following the issue
of shares detailed above the enlarged issued share capital of the Company will
comprise 88,065,661 ordinary shares of 2p each. The Company does not hold any
ordinary shares in treasury. The above figure may be used by shareholders as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company, under the Disclosure and Transparency Rules.

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                                     www.optibiotix.com (http://www.optibiotix.com/)
 Stephen O'Hara, Chief Executive  Contact via Walbrook below

 Cairn Financial Advisers LLP (NOMAD)                      Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Cenkos Securities plc (Broker)                            Tel: 020 7397 8900
 Callum Davidson / Neil McDonald
 Michael Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd                                           Mob: 07407 804 654
 Alice Woodings

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEZZGGFMRNGZZZ